Perrigo promotes McCormick to consumer healthcare pricing and planning manager
ALLEGAN, Mich. Perrigo earlier this week promoted Shawn McCormick to consumer healthcare pricing and planning manager, where he will be responsible for managing pricing and business planning functions within CHC marketing.
McCormick, a four-year Perrigo veteran, most recently served as the CHC sales and marketing controller. Before joining Perrigo, he worked for Steelcase in finance and with BDO Seidman in auditing.
A Certified Public Accountant, McCormick earned his Bachelor’s of Business Administration in Accounting from Grand Valley State University in 2001.
Arkray to offer MCT-Diabetes management system to patients
EDINA, Minn. Arkray on Wednesday announced that it will make MyCareTeam’s Internet-based diabetes management system available to patients, giving diabetes patients using the company’s Glucocard Blood Glucose Monitoring Systems the ability to monitor and manage their disease online and share real-time data with their healthcare providers.
“From our existing patient wellness program to our assortment of free education and support materials for patients and healthcare providers, Arkray has an obligation to extend every advantage to diabetes patients using our products,” stated Jonathan Chapman, Arkray president. “This agreement with MyCareTeam extends our commitment to patients by helping them go beyond monitoring their diabetes, and take steps toward actively managing it.”
MyCareTeam Inc. provides software tools designed for patients with chronic diseases. The company’s diabetes offering, MCT-Diabetes, has been successfully used for more than five years by patients, doctors and nurses to improve the health and wellness in people with diabetes, the company stated on its Web site.
Matrixx Initiatives confirms voluntary recall of two Zicam products
SCOTTSDALE, Ariz. Matrixx Initiatives has announced that it is in the process of formally notifying retailers, wholesalers and distributors nationwide of its recall of all Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs.
Matrixx Initiatives said that it vigorously disagreed with the FDA’s allegations that these products are not safe and that they were unlawfully marketed. However, the company reiterated that it is conducting this recall because of its desire to cooperate with the FDA. The company also is in the process of preparing a submission to the FDA and, as previously reported, will soon ask to meet with the agency to present comprehensive scientific and medical data and analyses demonstrating that these products are safe.
Matrixx Initiatives immediately suspended shipments of these two products upon receipt of the FDA’s warning letter on June 16, and then announced a voluntary nationwide withdrawal of Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs that same day. The company also is notifying retailers to stop selling Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs, and is asking them to post information at point-of-sale, advising consumers of the recall and inviting them to return these two products to Zicam for a full refund.
The company also has communicated on a proactive, ongoing basis with consumers since it announced the voluntary recall of these products. These have included full-page ads in leading newspapers, distribution of an informational video from Matrixx Initiatives’ president, updated copy for the Zicam Web site at www.zicam.com, expanding staffing of the Zicam customer support center and extensive use of social media vehicles.